{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:49:05Z","timestamp":1787003345957,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009318","name":"Helmholtz Association","doi-asserted-by":"publisher","award":["VH-VI-404"],"award-info":[{"award-number":["VH-VI-404"]}],"id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Data"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acquired resistance to chemotherapy is an important clinical problem and can also occur without detectable cytogenetic aberrations or gene mutations. Chronic lymphocytic leukemia (CLL) is molecularly well characterized and has been elemental for establishing central paradigms in oncology. This prompted us to check whether specific epigenetic changes at the level of DNA methylation might underlie development of treatment resistance. We used Illumina Infinium HumanMethylation450 BeadChips to obtain DNA methylation profiles of 71 CLL patients with differential responses. Thirty-six patients were categorized as relapsed\/refractory after treatment with fludarabine or bendamustine and 21 of them had genetic aberrations of\n                    <jats:italic>TP53<\/jats:italic>\n                    . The other 35 patients were untreated at the time of sampling and 15 of them had genetic aberration of\n                    <jats:italic>TP53<\/jats:italic>\n                    . Although we could not correlate chemoresistance with epigenetic changes, the patients were comprehensively characterized regarding relevant prognostic and molecular markers (e.g. IGHV mutation status, chromosome aberrations,\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation status, clinical parameters), which makes our dataset a unique and valuable resource that can be used by researchers to test alternative hypotheses.\n                  <\/jats:p>","DOI":"10.1038\/s41597-020-0456-0","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T06:02:39Z","timestamp":1588312959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5473-4398","authenticated-orcid":false,"given":"Deyan Yordanov","family":"Yosifov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bloehdorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-7188","authenticated-orcid":false,"given":"Daniel","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24282","volume":"91","author":"KR Rai","year":"2016","unstructured":"Rai, K. R. & Jain, P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol 91, 330\u2013340 (2016).","journal-title":"Am J Hematol"},{"key":"456_CR2","unstructured":"German Population-based Cancer Registry. German Centre for Cancer Registry Data (ZfKD) at the Robert Koch Institute, https:\/\/www.krebsdaten.de\/Krebs\/EN\/Database\/databasequery_step1_node.html (2017)."},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc2764","volume":"10","author":"T Zenz","year":"2010","unstructured":"Zenz, T., Mertens, D., Kuppers, R., Dohner, H. & Stilgenbauer, S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10, 37\u201350 (2010).","journal-title":"Nat Rev Cancer"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner, H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343, 1910\u20131916 (2000).","journal-title":"N Engl J Med"},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2017.291","volume":"32","author":"F Nadeu","year":"2018","unstructured":"Nadeu, F. et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia 32, 645\u2013653 (2018).","journal-title":"Leukemia"},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz, T. et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28, 4473\u20134479 (2010).","journal-title":"J Clin Oncol"},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.2443","volume":"44","author":"M Kulis","year":"2012","unstructured":"Kulis, M. et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 44, 1236\u20131242 (2012).","journal-title":"Nat Genet"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst, B. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17, 928\u2013942 (2016).","journal-title":"Lancet Oncol"},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer, K. et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127, 208\u2013215 (2016).","journal-title":"Blood"},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer, K. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30, 3209\u20133216 (2012).","journal-title":"J Clin Oncol"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating, M. J. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23, 4079\u20134088 (2005).","journal-title":"J Clin Oncol"},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt, T. D. et al. Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 381, 432\u2013443 (2019).","journal-title":"N Engl J Med"},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1097\/HS9.0000000000000175","volume":"3","author":"DY Yosifov","year":"2019","unstructured":"Yosifov, D. Y., Wolf, C., Stilgenbauer, S. & Mertens, D. From Biology to Therapy: The CLL Success Story. HemaSphere 3, e175 (2019).","journal-title":"HemaSphere"},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-018-0461-y","volume":"13","author":"T Hilal","year":"2018","unstructured":"Hilal, T., Betcher, J. A. & Leis, J. F. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty. Curr Hematol Malig Rep 13, 237\u2013243 (2018).","journal-title":"Curr Hematol Malig Rep"},{"key":"456_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1200\/JOP.2014.002469","volume":"11","author":"TD Shanafelt","year":"2015","unstructured":"Shanafelt, T. D. et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract 11, 252\u2013258 (2015).","journal-title":"J Oncol Pract"},{"key":"456_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.223","volume":"6","author":"GD te Raa","year":"2015","unstructured":"te Raa, G. D. et al. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. Cell Death Dis 6, e1852 (2015).","journal-title":"Cell Death Dis"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","volume":"114","author":"T Zenz","year":"2009","unstructured":"Zenz, T. et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114, 2589\u20132597 (2009).","journal-title":"Blood"},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","volume":"23","author":"L Yu","year":"2017","unstructured":"Yu, L. et al. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res 23, 735\u2013745 (2017).","journal-title":"Clin Cancer Res"},{"key":"456_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-115","volume":"9","author":"E Moussay","year":"2010","unstructured":"Moussay, E. et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 9, 115 (2010).","journal-title":"Mol Cancer"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-15-2903","volume":"22","author":"T Pandzic","year":"2016","unstructured":"Pandzic, T. et al. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. Clin Cancer Res 22, 6217\u20136227 (2016).","journal-title":"Clin Cancer Res"},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek, M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164\u20131174 (2010).","journal-title":"Lancet"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","volume":"114","author":"J Malcikova","year":"2009","unstructured":"Malcikova, J. et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 114, 5307\u20135314 (2009).","journal-title":"Blood"},{"key":"456_CR23","author":"DY Yosifov","year":"2020","unstructured":"Yosifov, D. Y. et al. DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. Gene Expression Omnibus, https:\/\/identifiers.org\/geo:GSE136724 (2020)."},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/nmeth.3115","volume":"11","author":"Y Assenov","year":"2014","unstructured":"Assenov, Y. et al. Comprehensive analysis of DNA methylation data with RnBeads. Nat Methods 11, 1138\u20131140 (2014).","journal-title":"Nat Methods"},{"key":"456_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1756-8935-6-4","volume":"6","author":"ME Price","year":"2013","unstructured":"Price, M. E. et al. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin 6, 4 (2013).","journal-title":"Epigenetics Chromatin"},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1093\/nar\/gkt090","volume":"41","author":"TJ Triche Jr.","year":"2013","unstructured":"Triche, T. J. Jr., Weisenberger, D. J., Van Den Berg, D., Laird, P. W. & Siegmund, K. D. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res 41, e90 (2013).","journal-title":"Nucleic Acids Res"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/bioinformatics\/bts680","volume":"29","author":"AE Teschendorff","year":"2013","unstructured":"Teschendorff, A. E. et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 29, 189\u2013196 (2013).","journal-title":"Bioinformatics"},{"key":"456_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4161\/epi.6.6.16216","volume":"6","author":"MA Sartor","year":"2011","unstructured":"Sartor, M. A. et al. Genome-wide methylation and expression differences in HPV(+) and HPV(\u2212) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6, 777\u2013787 (2011).","journal-title":"Epigenetics"},{"key":"456_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-199","volume":"15","author":"X Wang","year":"2014","unstructured":"Wang, X., Laird, P. W., Hinoue, T., Groshen, S. & Siegmund, K. D. Non-specific filtering of beta-distributed data. BMC Bioinformatics 15, 199 (2014).","journal-title":"BMC Bioinformatics"},{"key":"456_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2217\/epi.11.105","volume":"3","author":"S Dedeurwaerder","year":"2011","unstructured":"Dedeurwaerder, S. et al. Evaluation of the Infinium Methylation 450K technology. Epigenomics 3, 771\u2013784 (2011).","journal-title":"Epigenomics"},{"key":"456_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-13-0349","volume":"4","author":"CC Oakes","year":"2014","unstructured":"Oakes, C. C. et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov 4, 348\u2013361 (2014).","journal-title":"Cancer Discov"},{"key":"456_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1214\/09-STS290","volume":"24","author":"P Kraft","year":"2009","unstructured":"Kraft, P., Zeggini, E. & Ioannidis, J. P. Replication in genome-wide association studies. Stat Sci 24, 561\u2013573 (2009).","journal-title":"Stat Sci"},{"key":"456_CR33","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41591-018-0028-4","volume":"24","author":"R Beekman","year":"2018","unstructured":"Beekman, R. et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med 24, 868\u2013880 (2018).","journal-title":"Nat Med"},{"key":"456_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"EP Consortium","year":"2012","unstructured":"Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374 (2012).","journal-title":"Nature"},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature09906","volume":"473","author":"J Ernst","year":"2011","unstructured":"Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43\u201349 (2011).","journal-title":"Nature"}],"container-title":["Scientific Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41597-020-0456-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-020-0456-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-020-0456-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T23:47:37Z","timestamp":1670284057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41597-020-0456-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1038\/s41597-020-0456-0","relation":{"references":[{"id-type":"uri","id":"https:\/\/identifiers.org\/geo:GSE136724","asserted-by":"subject"}]},"ISSN":["2052-4463"],"issn-type":[{"value":"2052-4463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}